Status:
TERMINATED
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Lead Sponsor:
Pharmacyclics LLC.
Conditions:
Non-Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goals of this study are: * to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (NSCLC) wh...
Eligibility Criteria
Inclusion
- 18 years or older
- Stage IIIb, metastatic, or recurrent NSCLC patients who have received one prior platinum-based chemotherapy regimen
- ECOG performance status score of 0 or 1
Exclusion
- Laboratory values indicating inadequate function of bone marrow, liver, or kidneys
- Symptomatic or uncontrolled brain metastases
- Evidence of meningeal metastasis
- \> 1 prior regimen (not counting adjuvant or neo-adjuvant cytotoxic chemotherapy if completed \> 12 months prior to regiment)
- Medical condition that would increase risk if treated with motexafin gadolinium or impair ability to complete study procedures and assessments
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00365183
Start Date
June 1 2006
End Date
June 1 2008
Last Update
October 31 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntington Beach, California, United States
2
Long Beach, California, United States
3
Chicago, Illinois, United States
4
Baltimore, Maryland, United States